Here are three insights:
1. KCK Group led the financing round, which will also help support the investigational device exemption clinical trial of i-FACTOR in transforaminal lumbar interbody fusion surgery.
2. Cerapedics previously received FDA premarket approval for the use of i-FACTOR Peptide in anterior cervical discectomy and fusion procedures, becoming the first PMA-approved bone graft with this indication.
3. Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary biomimetic small peptide (P-15) technology platform. i‑FACTOR is the only biologic bone graft to incorporate a small peptide as an attachment factor to stimulate the natural bone healing process.
Here is more information on the i-FACTOR Peptide Enhanced Bone Graft.
More articles on biologics:
17 major players in the global spine biologics market
Dr. Chad Lavender performs ACL repair with bone marrow: 3 things to know
Stem cell therapy successfully repairs torn meniscus in case study: 4 findings
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
